OPTIMIZATION, DEVELOPMENT AND EVALUATION OF REPAGLINIDE CONTROLLED RELEASE GASTRO-RETENTIVE FLOATING TABLET USING CENTRAL COMPOSITE DESIGN

Authors

DOI:

https://doi.org/10.22159/ijap.2023v15i1.46493

Keywords:

gastro-retentive, floating tablet, central composite design, repaglinide, controlled release

Abstract

Objective: The recent study's objective was to optimize and formulate a controlled release gastro-retentive floating tablet of RG using a central composite design, which provides continuous release of Repaglinide for up to 24 hours.

Methods: Repaglinide gastro-retentive floating tablet (RG-GRF Tablet) was prepared by direct compression method. The optimization was carried out using a three-factor and three-level Central Composite design. The amount of Eudragit RSPO (A), HPMC K-100M (B) and Sodium bicarbonate (C) were selected as independent variables and the Cumulative % drug release in 1.5 hours (DR1.5), Cumulative % drug release in 8 hours (DR8), Cumulative % drug release in 24 hours (DR24) and Floating lag time (FLT) were used as dependent variables.

Results: CCD analysis results shows that predicted and experimental values for optimized formulation were found to be almost similar. Optimized amounts of Eudragit RSPO, HPMC K-100M, and NaHCO3 were 14.351mg, 44.438mg, and 10mg, respectively, with the highest possible desirability value of 0.898. The experimental values at optimized preparation conditions were found to be DR1.5 is 30.68%, DR8 is 64.90%, DR24 is 96.54%, and FLT is 4.41 min. The release data from the optimized formulation were closely matched with the Korsmeyer-Peppas model and in-vitro drug release studies indicated that the RG-GRF Tablet continuously releases the drug for 24 hours in a controlled manner.

Conclusion: Current research concludes that RG-GRF Tablets provide drug release for up to 24 h, and the derived central composite design can be used for forecasting the DR1.5, DR8 and DR24 as well. RG can also be made more bioavailable by extending the gastric residence time.

Downloads

Download data is not yet available.

References

Tripathi J, Thapa P, Maharjan R, Jeong SH. Current state and future perspectives on gastroretentive drug delivery systems. Pharmaceutics 2019;11(4). Epub 2019/04/24. doi: 10.3390/pharmaceutics11040193. PubMed PMID: 31010054; PubMed Central PMCID: PMCPMC6523542.

Sugihara H, Matsui Y, Takeuchi H, Wilding I, Connor A, Abe K, et al. Development of a gastric retentive system as a sustained-release formulation of pranlukast hydrate and its subsequent in vivo verification in human studies.Eur J Pharm Sci2014;53:62-8. doi: https://doi.org/10.1016/j.ejps.2013.11.018.

Sahu AK, Verma A. Development and statistical optimization of chitosan and eudragit based gastroretentive controlled release multiparticulate system for bioavailability enhancement of metformin HCl. J Pharm Invest 2016;46(3):239-52. doi: 10.1007/s40005-016-0229-0.

Vrettos NN, Roberts CJ, Zhu Z. Gastroretentive technologies in tandem with Controlled-release strategies: A potent answer to oral drug bioavailability and patient compliance implications. Pharmaceutics 2021;13(10). Epub 2021/10/24. doi: 10.3390/pharmaceutics13101591. PubMed PMID: 34683884; PubMed Central PMCID: PMCPMC8539558.

Mali AD, Bathe RS. Development and evaluation of gastroretentive floating tablets of a quinapril hcl by direct compression technique. Int J Pharm Pharm Sci 2017;9(8):35-46. doi: 10.22159/ijpps.2017v9i8.12463.

Lopes CM, Bettencourt C, Rossi A, Buttini F, Barata P. Overview on gastroretentive drug delivery systems for improving drug bioavailability. Int J Pharm 2016;510(1):144-58. Epub 2016/05/14. doi: 10.1016/j.ijpharm.2016.05.016. PubMed PMID: 27173823.

El-Houssieny BM, Wahman L, Arafa NM. Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits. Biosci Trends 2010;4(1):17-24. Epub 2010/03/23. PubMed PMID: 20305340.

Culy CR, Jarvis B. Repaglinide: A review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001;61(11):1625-60. Epub 2001/10/02. doi: 10.2165/00003495-200161110-00008. PubMed PMID: 11577798.

Ammar HO, El-feky GS, Ali AMA, Dawood RAG. Enhancement of oral bioavailability of repaglinide by self-nanoemulsifying drug delivery system. Int J Pharm Pharm Sci 2014;6(9):603-6.

Naveen R, Gopinath C, Rao D. Design expert supported mathematical optimization of repaglinide gastroretentive floating tablets: In vitro and in vivo evaluation. Future J Pharm Sci 2017;3. doi: 10.1016/j.fjps.2017.05.003.

Kohli S, Sharma M, Pal A. Ethylcellulose floating microspheres of antidiabetic agent: in vitro and in vivo evaluation. Int J Appl Pharm 2016;9(1):44-9. doi: 10.22159/ijap.2017v9i1.16139

Albetawi S, Abdalhafez A, Abu-Zaid A. A review on recent controlled release strategies for oral drug delivery of Repaglinide (a BCS Class II Drug). Pharm Nanotechnol 2021;9(5):326-38. Epub 2021/12/24. doi: 10.2174/2211738510666211221165318. PubMed PMID: 34939558.

Yin LF, Huang SJ, Zhu CL, Zhang SH, Zhang Q, Chen XJ, et al. In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier. Drug Dev Ind Pharm 2012;38(11):1371-80. Epub 2012/02/03. doi: 10.3109/03639045.2011.652635. PubMed PMID: 22296267.

Sopyan I, Gozali D, Sriwidodo, Guntina RK. Design-expert software (doe): an application tool for optimization in pharmaceutical preparations formulation. Int J Appl Pharm 2022;14(4):55-63. doi: 10.22159/ijap.2022v14i4.45144.

He W, Wu M, Huang S, Yin L. Matrix tablets for sustained release of repaglinide: Preparation, pharmacokinetics and hypoglycemic activity in beagle dogs. Int J Pharm 2015;478(1):297-307. Epub 2014/12/02. doi: 10.1016/j.ijpharm.2014.11.059. PubMed PMID: 25434592.

Srinivas I, Bhikshapathi DVRN. Preparation and in-vivo evaluation of solid dispersions using Repaglinide. Int J Pharm Sci Drug Res 2018;10(5). doi: 10.25004/IJPSDR.2018.100502.

Dhole SM, Khedekar PB, Amnerkar ND. Comparison of UV spectrophotometry and high performance liquid chromatography methods for the determination of repaglinide in tablets. Pharm Methods 2012;3(2):68-72. Epub 2013/06/20. doi: 10.4103/2229-4708.103875. PubMed PMID: 23781481; PubMed Central PMCID: PMCPMC3658086.

Naveen NR, Gopinath C, Rao DS. Design expert supported mathematical optimization of repaglinide gastroretentive floating tablets: In vitro and in vivo evaluation. Future J Pharm Sci 2017;3(2):140-7. doi: https://doi.org/10.1016/j.fjps.2017.05.003.

Barmpalexis P, Kachrimanis K, Malamataris S. Statistical moments in modelling of swelling, erosion and drug release of hydrophilic matrix-tablets. Int J Pharm 2018;540(1-2):1-10. Epub 2018/02/07. doi: 10.1016/j.ijpharm.2018.01.052. PubMed PMID: 29407874.

Charoenying T, Patrojanasophon P, Ngawhirunpat T, Rojanarata T, Akkaramongkolporn P, Opanasopit P. Design and optimization of 3D-Printed gastroretentive floating devices by Central Composite Design. AAPS PharmSciTech 2021;22(5):197. Epub 2021/07/01. doi: 10.1208/s12249-021-02053-3. PubMed PMID: 34191172.

Pawar MA, Shevalkar GB, Vavia PR. Design and development of Gastro-retentive drug delivery system for Trazodone Hydrochloride: a Promising alternative to innovator's Controlled-Release tablet. AAPS PharmSciTech 2022;23(7):251. Epub 2022/09/08. doi: 10.1208/s12249-022-02404-8. PubMed PMID: 36071254.

Chambin O, Champion D, Debray C, Rochat-Gonthier MH, Le Meste M, Pourcelot Y. Effects of different cellulose derivatives on drug release mechanism studied at a preformulation stage. J Control Release 2004;95(1):101-8. Epub 2004/03/12. doi: 10.1016/j.jconrel.2003.11.009. PubMed PMID: 15013237.

Grund J, Körber M, Bodmeier R. Predictability of drug release from water-insoluble polymeric matrix tablets. Eur J Pharm Biopharm 2013;85(3 Pt A):650-5. Epub 2013/08/30. doi: 10.1016/j.ejpb.2013.08.007. PubMed PMID: 23985775.

Maderuelo C, Zarzuelo A, Lanao JM. Critical factors in the release of drugs from sustained release hydrophilic matrices. J Controlled Release 2011;154(1):2-19. doi: https://doi.org/10.1016/j.jconrel.2011.04.002.

Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13(2):123-33. Epub 2001/04/12. doi: 10.1016/s0928-0987(01)00095-1. PubMed PMID: 11297896.

Homayoonfal M, Khodaiyan F, Mousavi M. Modelling and optimising of physicochemical features of walnut-oil beverage emulsions by implementation of response surface methodology: Effect of preparation conditions on emulsion stability. Food Chemistry 2015;174:649-59. doi: https://doi.org/10.1016/j.foodchem.2014.10.117.

Myers RH, Montgomery DC, Anderson-Cook CM. Response surface methodology: process and product optimization using designed experiments: John Wiley & Sons; 2016.

Published

09-11-2022

How to Cite

PATEL, M., & KHAN, M. A. (2022). OPTIMIZATION, DEVELOPMENT AND EVALUATION OF REPAGLINIDE CONTROLLED RELEASE GASTRO-RETENTIVE FLOATING TABLET USING CENTRAL COMPOSITE DESIGN. International Journal of Applied Pharmaceutics, 15(1). https://doi.org/10.22159/ijap.2023v15i1.46493

Issue

Section

Original Article(s)